What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report Gilead Sciences, Inc.'s financial results for the first quarter ended March 31, 2004, as announced in an accompanying press release.

Why is Gilead Sciences using non-GAAP financial measures in this report?

Gilead is using non-GAAP financial measures to provide investors with a clearer view of its core business performance. They are excluding a significant gain from an equity investment in Eyetech Pharmaceuticals, Inc. resulting from Eyetech's IPO, as this transaction is considered unusual in nature, size, and frequency.

What specific unusual event is being excluded from Gilead's reported results?

The specific unusual event being excluded is the gain realized from Gilead's equity investment in Eyetech Pharmaceuticals, Inc., which became significant due to Eyetech's public offering completed in the first quarter of 2004.

Who is John F. Milligan and what is his role?

John F. Milligan is identified as the Executive Vice President and Chief Financial Officer of Gilead Sciences, Inc. He signed the report on behalf of the company, indicating his responsibility for the financial disclosures.

GILD 8-K SEC Disclosure

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on April 22, 2004, to report its financial results for the quarter ended March 31, 2004, as detailed in an accompanying press release (Exhibit 99.1). The filing highlights the company's use of non-GAAP financial measures, specifically to exclude a significant, unusual, and infrequent gain on an equity investment related to the initial public offering (IPO) of Eyetech Pharmaceuticals, Inc. during the first quarter of 2004. Management utilizes these non-GAAP figures to better assess ongoing operational performance and trends, excluding the impact of this one-time transaction. Gilead believes this approach offers investors a clearer perspective on the underlying financial health and core business performance, distinct from the substantial, non-recurring gain realized from the Eyetech investment.

Key Highlights

1Gilead Sciences announced its financial results for the first quarter ended March 31, 2004.
2The company issued a press release (Exhibit 99.1) detailing these results, filed as part of the 8-K.
3A key focus of the filing is the use of non-GAAP financial measures.
4These non-GAAP measures are presented to exclude a gain on equity investment from Eyetech Pharmaceuticals, Inc.'s public offering.
5The gain from the Eyetech IPO is characterized as unusual, large, and infrequent.
6Management uses these non-GAAP metrics to monitor ongoing results and trends impacting the core business.
7Gilead believes these non-GAAP insights are valuable for investors seeking to understand core operational performance.

GILEAD SCIENCES, INC. 8-K Report (Apr 22, 2004)

Summary

Key Highlights

Frequently Asked Questions